Sexual Health & Bonding

PT-141

Bremelanotide · Vyleesi · melanocortin agonist

FDA-approved popular subQ injection / nasal

What it is

PT-141 (bremelanotide) is a synthetic analog of α-MSH (alpha-melanocyte-stimulating hormone). It was originally developed as a tanning agent (similar to Melanotan II) until researchers noticed unexpected libido-boosting effects. FDA-approved in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder. Used off-label in men for erectile dysfunction and libido.

How it works

Unlike Viagra/Cialis (which work on blood vessels), PT-141 acts on the brain. It activates melanocortin receptors (specifically MC4R) in the hypothalamus — the brain region that controls sexual behavior, arousal, and motivation.

This means it works for psychological/desire-based sexual dysfunction, not just mechanical/vascular issues. It's also independent of testosterone — people with low T who don't respond to PDE5 inhibitors often respond to PT-141.

Benefits

Increased sexual desire (works in both sexes)
Improved arousal independent of testosterone or vascular function
Effective for sildenafil non-responders in male trials (~33% achieved erection vs 8.5% placebo)
Works centrally — useful for stress/anxiety-related sexual dysfunction
Effects last 6–72 hours after a single dose
FDA-approved safety profile in women

Timeline

30–45 min: Onset of arousal and desire effects.
2–6 hours: Peak effect window. Use timing accordingly.
24–72 hours: Lingering subtle effects in some users.
Repeat: Use as-needed, not daily. Frequent use can lead to tolerance and side effects.

Dosing & titration

Starting dose0.5–1.0 mg subQ injection (test for tolerability)

Standard dose (women)1.75 mg subQ (FDA-approved Vyleesi dose)

Standard dose (men, off-label)1–2 mg subQ

Intranasal alternative2–6 mg via nasal spray (less consistent dosing but more discreet)

FrequencyAs-needed only. Do not exceed 8 doses per month or one dose per 24-hour period.

When to titrate upIf 1 mg has minimal effect, try 1.75 mg next time. Don't exceed 2 mg per dose — nausea risk increases significantly without added benefit.

Side effects & risks

Nausea (most common, ~40% of users; usually first dose only)
Flushing (face and chest)
Headache
Mild blood pressure increase (transient ~30 min after dosing)
Skin darkening with chronic use (similar to Melanotan)
Rare: priapism (prolonged erection > 4 hours)
Rare: focal hyperpigmentation, especially around freckles or moles

BP caveat: Avoid in uncontrolled hypertension or known cardiovascular disease. The transient BP bump is mild but real. Don't combine with alcohol on first use — nausea risk compounds. Get baseline mole/skin check — chronic use can darken pigmented lesions.

Typical price

$80–$200/mo Compounded subQ vials from a 503A pharmacy. Branded Vyleesi single-use auto-injector pens are ~$300+ per dose retail.

Studies

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder — Pivotal Phase 3 trials (RECONNECT) supporting FDA approval. PubMed Central Annals of Pharmacotherapy, 2022
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial — Established 1.25–1.75 mg dosing. PubMed Central Women's Health, 2016
PT-141: a melanocortin agonist for the treatment of sexual dysfunction — Original characterization paper. PubMed Annals of the New York Academy of Sciences, 2003
Long-Term Safety and Efficacy of Bremelanotide for HSDD — 52-week safety extension data. Obstetrics & Gynecology Obstetrics & Gynecology, 2019

Educational reference only. Not medical advice. PT-141 (Vyleesi) is FDA-approved for premenopausal HSDD; off-label uses (men, ED, etc.) should be supervised by a licensed prescriber.